Following in the footsteps of Celltrion (Kosdaq: 068270), Samsung Bioepis, Amgen (Nasdaq: AMGN) and others, Prestige BioPharma is making headway with its Herceptin (trastuzumab) biosimilar.
The Singapore-based company has had its marketing authorization application (MAA) approved by the European Medicines Agency (EMA), giving it the chance of reaching a major market with a copy of the Roche (ROG: SIX) drug, which is indicated for HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Prestige’s Phase I/III data on its HD201 candidate includes results showing exceptional biosimilarity to Herceptin in terms of clinical response and pharmacokinetics, and a comparable safety profile to the range previously observed in Herceptin biosimilar trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze